https://ir.kiorapharma.com/ https://ir.kiorapharma.com/news-events/news-releases https://ir.kiorapharma.com/news-events/events https://ir.kiorapharma.com/news-events/presentations https://ir.kiorapharma.com/news-events/email-alerts https://ir.kiorapharma.com/company-information https://ir.kiorapharma.com/company-information/executive-team https://ir.kiorapharma.com/company-information/contacts https://ir.kiorapharma.com/company-information/faq https://ir.kiorapharma.com/company-information/analyst-coverage https://ir.kiorapharma.com/sec-filings/all-sec-filings https://ir.kiorapharma.com/sec-filings/annual-reports https://ir.kiorapharma.com/sec-filings/quarterly-reports https://ir.kiorapharma.com/sec-filings/section-16-filings https://ir.kiorapharma.com/financial-information/financial-results https://ir.kiorapharma.com/financial-information/income-statement https://ir.kiorapharma.com/financial-information/balance-sheet https://ir.kiorapharma.com/financial-information/cash-flow https://ir.kiorapharma.com/governance https://ir.kiorapharma.com/news-events/news-releases/detail/246/kiora-pharmaceuticals-announces-management-team-changes 2026-04-02T16:30:41-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/245/kiora-pharmaceuticals-reports-fourth-quarter-and-full-year-2025-results-company-advances-retinal-disease-pipeline-with-two-active-phase-2-clinical-trials 2026-03-25T07:00:55-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/244/kiora-pharmaceuticals-to-present-at-oppenheimers-36th-annual-healthcare-life-sciences-conference 2026-02-19T08:31:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/243/retinal-disease-expert-dr-taiji-sakamoto-joins-kiora-pharmaceuticals-scientific-advisory-board 2026-01-27T07:00:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/242/kiora-pharmaceuticals-granted-u-s-patent-covering-additional-formulations-for-the-kio-100-family-of-anti-inflammatory-compounds 2025-12-01T06:45:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/241/kiora-pharmaceuticals-reports-third-quarter-2025-results-company-advances-pipeline-with-two-actively-enrolling-phase-2-clinical-trials-for-retinal-diseases 2025-11-07T06:01:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/240/kiora-pharmaceuticals-joins-rare-x-vision-consortium-promoting-collaboration-and-development-of-new-treatments-for-rare-ocular-disorders 2025-10-30T09:44:21-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/239/kiora-pharmaceuticals-to-participate-in-the-2025-maxim-growth-summit-and-eyecelerator-aao-2025 2025-10-15T07:00:49-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/238/kiora-pharmaceuticals-to-webcast-on-demand-presentation-at-the-h-c-wainwright-27th-annual-global-investment-conference 2025-09-04T07:01:26-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/237/kiora-pharmaceuticals-reports-second-quarter-2025-results-company-advances-pipeline-with-two-active-phase-2-clinical-trials-for-retinal-diseases 2025-08-08T07:00:57-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/236/kiora-pharmaceuticals-to-showcase-its-retinal-disease-therapeutic-pipeline-at-the-h-c-wainwright-5th-annual-ophthalmology-virtual-conference 2025-08-07T07:01:39-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/235/kiora-pharmaceuticals-granted-u-s-patent-expanding-protection-for-kio-104-in-the-treatment-of-ocular-disease 2025-07-22T08:55:41-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/234/kiora-pharmaceuticals-and-senju-pharmaceutical-partner-on-kio-301-for-the-treatment-of-retinal-diseases-in-asia 2025-06-03T07:01:30-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/233/kiora-pharmaceuticals-reports-first-quarter-results-initiating-two-phase-2-trials-for-treatment-of-retinal-diseases-cash-and-short-term-investments-expected-to-fund-operations-into-late-2027 2025-05-09T07:01:08-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/232/kiora-pharmaceuticals-presents-in-vivo-preclinical-data-at-arvo-2025-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy 2025-05-05T07:01:09-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/231/kiora-pharmaceuticals-to-present-at-the-24th-annual-needham-virtual-healthcare-conference 2025-04-05T11:42:36-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/230/kiora-pharmaceuticals-reports-2024-results-retinal-disease-drug-development-pipeline-continues-to-advance-cash-and-short-term-investments-expected-to-fund-operations-into-2027 2025-03-25T07:00:56-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/229/kiora-pharmaceuticals-to-present-preclinical-data-on-kio-104-for-the-treatment-of-proliferative-vitreoretinopathy-at-the-arvo-2025-annual-meeting 2025-03-12T07:01:05-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/228/kiora-pharmaceuticals-secures-u-s-composition-of-matter-patent-expanding-protection-of-its-anti-inflammatory-compound-kio-104 2025-02-13T07:01:04-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/227/kiora-receives-approval-to-initiate-klarity-a-phase-2-clinical-trial-of-kio-104-for-the-treatment-of-retinal-macular-edema 2025-02-11T06:45:38-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/226/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing-two-phase-2-studies 2024-11-08T07:00:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/225/kiora-pharmaceuticals-receives-investigational-new-drug-approval-to-initiate-abacus-2-a-phase-2-clinical-trial-of-kio-301-for-the-treatment-of-retinitis-pigmentosa 2024-10-29T06:45:37-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/224/kiora-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2024-09-25T10:02:17-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/223/kiora-pharmaceuticals-reports-second-quarter-results-retinal-disease-drug-development-pipeline-advancing-toward-two-phase-2-studies 2024-08-09T07:00:34-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/222/kiora-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2024-08-06T07:03:25-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/221/kiora-pharmaceuticals-receives-european-orphan-medicinal-product-designation-for-kio-301-for-the-treatment-of-inherited-retinal-dystrophies 2024-07-30T06:45:29-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/220/kiora-pharmaceuticals-to-participate-in-jones-healthcare-seaside-summit-2024-kiora-invites-investors-to-submit-questions-following-the-conference-presentation 2024-07-10T07:00:36-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/219/biotech-executive-lisa-walters-hoffert-joins-kiora-pharmaceuticals-board-of-directors 2024-07-01T06:54:15-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/218/vitreoretinal-surgeon-and-key-thought-leader-roger-goldberg-m-d-joins-kiora-pharmaceuticals-scientific-advisory-board 2024-06-25T06:45:28-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/217/kiora-to-enact-1-for-9-reverse-split-on-june-11th 2024-06-07T07:15:35-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/215/kiora-pharmaceuticals-to-participate-in-upcoming-investor-conferences 2024-05-20T07:00:34-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/214/kiora-pharmaceuticals-reports-first-quarter-results-update-on-pipeline-of-drugs-targeting-retinal-disease 2024-05-10T07:00:30-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/213/kiora-pharmaceuticals-to-present-at-the-citizens-jmp-life-sciences-conference 2024-05-08T07:00:51-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/212/kiora-pharmaceuticals-reports-additional-clinical-data-for-kio-301-showing-a-statistically-significant-increase-in-brain-activity-in-the-visual-cortex-in-patients-with-retinitis-pigmentosa 2024-05-06T07:00:32-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/211/kiora-pharmaceuticals-receives-grant-from-choroideremia-research-foundation-to-fund-novel-clinical-trial-endpoints-for-inherited-retinal-diseases-approval-granted-to-initiate-clinical-validation-study 2024-04-11T07:00:35-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/210/kiora-pharmaceuticals-to-present-at-upcoming-investor-conferences 2024-04-05T07:00:33-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/209/kiora-pharmaceuticals-to-present-additional-data-from-its-abacus-1-trial-in-retinitis-pigmentosa-at-the-arvo-2024-annual-meeting 2024-03-28T06:45:27-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/208/kiora-pharmaceuticals-reports-2023-results-continues-to-advance-pipeline-of-treatments-for-rare-retinal-diseases 2024-03-25T07:00:33-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/207/kiora-announces-publication-of-phase-1-study-demonstrating-safety-tolerability-and-anti-inflammatory-activity-of-kio-101-in-the-treatment-of-inflammation-of-the-eye 2024-03-08T07:00:30-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/206/kiora-pharmaceuticals-announces-private-placement-of-up-to-approximately-45-million 2024-01-31T18:40:19-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/205/kiora-pharmaceuticals-and-tha-open-innovation-enter-strategic-agreement-to-develop-and-commercialize-kio-301-for-the-treatment-of-inherited-retinal-diseases-total-deal-value-of-up-to-301-million-includes-16-million-upfront-up-to-285-million-in-clinical-development-regulatory-and-commercial-milestones-plus-commercial-royalties 2024-01-31T17:15:34-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/204/kiora-pharmaceuticals-reports-q3-2023-results-expanding-clinical-development-of-kio-301-for-inherited-retinal-diseases-based-on-encouraging-results-of-abacus-1-study-in-retinitis-pigmentosa 2023-11-09T07:18:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/203/aao-late-breaking-kioras-small-molecule-photoswitch-demonstrates-meaningful-vision-improvements-in-blind-patients-with-retinitis-pigmentosa 2023-11-04T12:15:31-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/202/kiora-pharmaceuticals-to-participate-in-the-lytham-partners-fall-2023-investor-conference 2023-11-03T13:30:40-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/201/kiora-pharmaceuticals-receives-investigational-new-drug-application-approval-to-expand-phase-1b-study-of-kio-301-in-inherited-retinal-diseases-to-enroll-patients-with-choroideremia-and-additional-patients-with-late-stage-retinitis-pigmentosa 2023-10-03T07:00:33-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/200/kiora-pharmaceuticals-appoints-praveen-tyle-phd-as-new-chairman-succeeds-paul-chaney-who-is-retiring-after-serving-17-years 2023-09-21T07:00:32-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/199/kiora-pharmaceuticals-completes-last-patient-last-visit-in-phase-1b-trial-of-kio-301-in-patients-with-retinitis-pigmentosa 2023-09-18T07:00:31-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/198/kiora-pharmaceuticals-to-present-topline-results-from-the-abacus-study-at-american-academy-ophthalmology-aao-phase-1b-study-evaluating-kio-301-in-retinitis-pigmentosa 2023-09-14T07:01:43-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/197/new-approaches-for-inherited-retinal-disease-webinar-replay 2023-09-01T12:23:36-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/196/kiora-pharmaceuticals-adjourns-special-meeting-of-stockholders-to-september-27 2023-09-01T07:00:20-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/195/kiora-proxy-vote-deadline---thur-aug-31-at-noon 2023-08-29T14:30:50-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/194/kiora-pharmaceuticals-and-the-choroideremia-research-foundation-to-host-webinar-on-the-development-of-molecular-photoswitches-for-inherited-retinal-diseases 2023-08-29T13:43:11-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/193/kiora-pharmaceuticals-granted-u-s-and-european-patents-for-local-ocular-delivery-of-the-kio-100-family-of-compounds-new-ip-specifically-includes-treatment-of-posterior-non-infectious-uveitis 2023-08-23T07:00:26-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/192/kiora-pharmaceuticals-webcasts-its-investor-presentation-from-the-h-c-wainwright-3rd-annual-ophthalmology-virtual-conference 2023-08-16T07:00:21-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/191/q2-business-update-view-kioras-latest-presentation-detailing-our-sharpened-focus-on-orphan-retinal-disease 2023-08-08T08:38:51-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/190/kiora-pharmaceuticals-announces-q2-2023-earnings-and-business-update-highlighting-pipeline-updates-and-clinical-development-progress 2023-08-08T07:00:24-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/189/kiora-pharmaceuticals-inc-and-choroideremia-research-foundation-partner-to-advance-novel-choroideremia-treatment 2023-08-03T07:01:20-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/187/let-there-be-light-a-spotlight-on-kioras-flagship-product-kio-301-which-aims-to-restore-vision-for-patients-with-a-rare-inherited-retinal-disease 2023-08-02T09:16:48-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/188/biotech-leader-carmine-stengone-joins-kiora-pharmaceuticals-board-of-directors 2023-08-01T07:00:20-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/186/kiora-pharmaceuticals-receives-1-2-million-in-research-tax-credits-to-advance-the-treatment-of-ophthalmic-disease 2023-07-05T07:00:38-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/185/kiora-pharmaceuticals-and-sentrx-animal-care-amend-existing-manufacturing-licensing-agreement-for-kio-201 2023-06-15T07:00:24-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/184/kiora-pharmaceuticals-to-present-at-upcoming-investor-conferences 2023-06-14T08:00:26-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/183/kiora-pharmaceuticals-announces-closing-of-6-3-million-underwritten-public-offering-and-full-exercise-of-over-allotment-option 2023-06-06T16:30:19-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/182/kiora-pharmaceuticals-announces-pricing-of-5-5-million-underwritten-public-offering 2023-06-02T08:30:25-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/181/kiora-pharmaceuticals-reports-first-quarter-results-positive-clinical-data-driving-significant-progress-advancing-pipeline-of-eye-disease-treatments 2023-05-09T07:02:02-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/180/kiora-pharmaceuticals-presents-encore-imaging-results-of-kio-301-for-retinitis-pigmentosa-at-asnr-2023-meeting 2023-05-01T07:00:24-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/179/kioras-investigational-treatment-for-retinitis-pigmentosa-kio-301-demonstrates-visual-function-restoration-in-patients-who-are-blind 2023-04-27T14:55:19-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/178/kiora-pharmaceuticals-kio-201-heals-wounds-in-phase-2-trial-of-patients-with-persistent-corneal-epithelial-defects 2023-04-26T07:00:27-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/177/inherited-retinal-disease-expert-mark-pennesi-m-d-ph-d-joins-kiora-pharmaceuticals-scientific-advisory-board 2023-04-21T07:00:22-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/176/kiora-pharmaceuticals-initiates-phase-2-trial-of-kio-101-for-the-treatment-of-ocular-presentation-of-autoimmune-diseases 2023-04-17T07:00:24-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/175/kiora-announces-the-acceptance-of-late-breaking-abstract-on-phase-1b-study-of-kio-301-in-retinitis-pigmentosa-at-the-american-society-of-neuroradiology-2023-meeting 2023-03-30T07:00:23-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/174/kiora-pharmaceuticals-reports-2022-financial-results-provides-update-on-clinical-development-progress 2023-03-23T07:00:31-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/173/kiora-pharmaceuticals-announces-the-acceptance-of-three-abstracts-at-the-2023-arvo-annual-meeting 2023-03-10T07:00:26-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/172/kiora-pharmaceuticals-receives-investigational-new-drug-approval-for-phase-2-study-of-kio-101-for-treatment-of-ocular-presentation-of-autoimmune-diseases 2023-02-07T07:00:28-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/171/kiora-pharmaceuticals-enters-into-two-equity-purchase-agreements-with-lincoln-park-capital 2023-02-03T07:00:23-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/170/kiora-pharmaceuticals-highlights-anticipated-clinical-and-corporate-milestones-for-2023-webcast-now-available-on-company-website 2023-01-09T07:00:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/169/kiora-pharmaceuticals-completes-enrollment-of-clinical-trial-evaluating-kio-201-for-persistent-corneal-epithelial-defects-results-expected-to-be-reported-in-1h-2023 2023-01-03T07:01:19-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/168/kiora-pharmaceuticals-enters-into-agreements-to-raise-3-12-million-from-the-exercise-of-previously-issued-class-a-warrants 2022-11-18T08:30:18-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/167/kiora-pharmaceuticals-doses-first-patient-in-abacus-phase-1b-study-evaluating-kio-301-for-retinitis-pigmentosa 2022-11-17T06:45:22-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/166/kiora-pharmaceuticals-provides-3rd-quarter-2022-business-and-financial-update-dosing-of-kio-301-in-phase-1-trial-for-retinitis-pigmentosa-to-begin-before-years-end 2022-11-09T06:45:22-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/165/kiora-pharmaceuticals-announces-publication-of-phase-1-trial-results-for-kio-100-as-a-treatment-for-ocular-inflammatory-disease 2022-10-17T08:00:24-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/164/kiora-pharmaceuticals-regains-compliance-with-nasdaq-listing-requirements 2022-10-13T06:45:19-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/163/battling-blindness-virtual-investor-event-on-treatments-for-retinitis-pigmentosa-to-be-held-oct-19-panelists-include-kiora-pharmaceuticals-foundation-fighting-blindness-and-retinal-surgeon-christine-kay-m-d 2022-10-12T09:29:13-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/162/kiora-pharmaceuticals-to-implement-1-for-40-reverse-split 2022-09-26T06:45:18-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/161/kiora-pharmaceuticals-to-participate-in-the-ladenburg-thalmann-2022-healthcare-conference 2022-09-15T12:25:07-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/160/kiora-pharmaceuticals-appoints-melissa-tosca-as-executive-vice-president-of-finance 2022-09-13T06:45:23-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/159/im-going-blind-this-is-what-i-want-to-you-see---nyt-short-film-on-rp 2022-08-16T14:46:48-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/158/kiora-pharmaceuticals-reports-first-half-2022-business-update-and-financial-results 2022-08-12T06:45:21-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/157/kiora-pharmaceuticals-to-participate-in-the-h-c-wainwright-2nd-annual-ophthalmology-virtual-conference-online-presentation-will-be-available-august-17-2022-at-7-00-am-est 2022-08-09T11:20:04-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/156/kiora-pharmaceuticals-issued-us-patent-covering-kio-201-technology-in-combination-with-antibiotics 2022-07-28T06:45:21-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/155/kiora-pharmaceuticals-announces-closing-of-6-0-million-underwritten-public-offering-and-full-exercise-of-over-allotment-option 2022-07-26T16:38:41-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/154/kiora-pharmaceuticals-announces-pricing-of-5-2-million-underwritten-public-offering 2022-07-22T08:30:23-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/153/kiora-pharmaceuticals-announces-first-patient-enrolled-in-phase-2-study-evaluating-kio-201-for-persistent-corneal-epithelial-defects 2022-07-05T06:45:20-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/152/kiora-pharmaceuticals-receives-clinical-trial-approval-for-first-in-human-evaluation-of-kio-301-to-restore-vision-in-patients-with-retinitis-pigmentosa 2022-06-27T06:53:02-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/151/kiora-pharmaceuticals-receives-nasdaq-notification-of-non-compliance-with-listing-rule-5250c1 2022-05-31T16:30:22-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/150/kiora-pharmaceuticals-announces-presentation-of-kio-101-clinical-trial-data-at-the-american-society-of-cataract-and-refractive-surgery-2022 2022-04-25T06:45:20-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/149/kiora-pharmaceuticals-reports-2021-results-and-provides-business-update 2022-04-15T09:00:21-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/148/kiora-pharmaceuticals-to-participate-in-maxim-groups-2022-virtual-growth-conference-march-28th---30th 2022-03-21T06:45:19-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/147/kiora-pharmaceuticals-granted-orphan-drug-designation-for-kio-301-an-investigational-drug-for-the-treatment-of-retinitis-pigmentosa-rp 2022-03-18T06:45:17-04:00 https://ir.kiorapharma.com/news-events/news-releases/detail/146/kiora-pharmaceuticals-announces-participation-at-2022-bio-ceo-investor-conference 2022-02-08T06:45:22-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/145/kiora-pharmaceuticals-appoints-erin-parsons-to-its-board-of-directors-stephen-from-to-retire-from-board 2022-02-01T06:45:27-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/5/kiora-pharmaceuticals-to-provide-2022-business-outlook-at-the-h-c-wainwright-bioconnect-virtual-conference 2022-01-05T12:14:25-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/6/kiora-pharmaceuticals-appoints-david-hollander-md-mba-to-its-board-of-directors 2022-01-05T12:14:25-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/7/kiora-reports-kio-101-is-safe-and-tolerable-topline-data-supports-advancing-kio-101-to-a-phase-2-study-in-patients-with-dry-eye-disease 2022-01-05T12:14:25-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/8/kiora-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides-business-update 2022-01-05T12:14:25-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/9/eyegate-is-now-kiora-pharmaceuticals-provides-update-on-companys-sharpened-clinical-development-strategy 2022-01-05T12:14:25-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/10/eyegate-pharmaceuticals-appoints-eric-j-daniels-md-mba-as-chief-development-officer-and-closes-acquisition-of-bayon-therapeutics-inc 2022-01-19T14:36:41-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/11/eyegate-to-present-at-the-h-c-wainwright-23rd-annual-global-investment-conference 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/12/eyegate-pharma-completes-target-enrollment-in-phase-2-proof-of-concept-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/13/eyegate-pharma-reports-second-quarter-2021-financial-results-and-provides-business-update 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/14/eyegate-announces-closing-of-10-75-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/15/eyegate-announces-10-75-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/16/eyegate-pharmaceuticals-announces-appointment-of-brian-m-strem-ph-d-as-president-and-chief-executive-officer 2022-01-19T14:36:42-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/17/eyegate-pharma-announces-first-patient-dosed-for-pp-001-in-a-phase-2-proof-of-concept-ocular-surface-inflammation-study 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/18/eyegate-pharma-reports-first-quarter-2021-financial-results-and-provides-business-update 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/19/eyegate-pharma-announces-the-appointment-of-kenneth-gayron-and-aron-shapiro-to-its-board-of-directors 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/20/eyegate-pharma-reports-full-year-2020-financial-results-and-provides-business-update 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/21/eyegate-pharmaceuticals-announces-management-transition-in-support-of-strategic-transformation 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/22/eyegate-enters-into-agreement-for-8-0-million-private-placement 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/23/eyegate-pharma-announces-transformative-acquisition-of-panoptes-pharma 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/24/eyegate-pharma-reports-third-quarter-2020-financial-results-and-provides-business-update 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/25/eyegate-pharma-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference 2022-01-19T14:36:43-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/26/eyegate-pharma-confirms-path-forward-with-fda-to-develop-combination-product 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/27/eyegate-pharma-reports-second-quarter-2020-financial-results-and-provides-business-update 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/28/eyegate-pharma-to-proceed-with-pe-pivotal-study 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/29/eyegate-pharma-receives-positive-feedback-from-fda-regarding-ocular-bandage-gel-packaging 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/30/eyegate-pharma-to-present-at-jefferies-2020-virtual-healthcare-conference 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/31/eyegate-pharma-reports-first-quarter-2020-financial-results-and-provides-business-update 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/32/eyegate-pharma-announces-positive-topline-data-in-follow-on-dry-eye-pilot-study 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/33/eyegate-pharma-completes-enrollment-in-follow-on-pe-pilot-study 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/34/eyegate-announces-completion-of-5-0-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/35/eyegate-pharma-receives-1-9-million-from-exercised-warrants 2022-01-19T14:36:44-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/36/eyegate-pharma-announces-additional-positive-top-line-data-in-prk-pivotal-study 2022-01-19T14:36:45-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/37/eyegate-pharma-hits-primary-endpoint-in-prk-pivotal-study 2022-01-19T14:36:45-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/38/eyegate-pharma-reports-third-quarter-2019-financial-results-and-provides-business-update 2022-01-19T14:36:45-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/40/eyegate-pharma-enrolls-first-patient-in-follow-on-pe-pilot-study 2022-01-19T14:36:45-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/39/eyegate-pharma-completes-randomization-in-pivotal-study 2022-01-19T14:36:45-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/41/eyegate-enters-into-agreement-for-1-9-million-private-placement 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/42/eyegate-pharma-regains-nasdaq-listing-compliance 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/43/eyegate-pharma-reaches-75-randomization-of-patients-in-pivotal-study 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/44/eyegate-pharma-to-present-at-h-c-wainwright-21st-annual-global-investment-conference 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/45/eyegate-pharma-announces-reverse-stock-split-effective-august-30-2019 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/46/eyegate-pharma-reaches-50-randomization-of-patients-in-pivotal-study 2022-01-19T14:36:46-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/47/eyegate-pharma-reports-second-quarter-2019-financial-results-and-provides-business-update 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/48/eyegate-pharma-receives-approval-from-fda-to-initiate-pe-pilot-study 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/49/eyegate-pharma-announces-randomization-of-first-25-of-patients-in-pivotal-study 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/50/eyegate-files-fda-submission-to-initiate-pe-pilot-study 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/51/eyegate-announces-first-patient-enrolled-in-prk-pivotal-study 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/52/eyegate-receives-approval-from-fda-to-initiate-prk-pivotal-study 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/53/eyegate-pharma-receives-positive-nasdaq-listing-determination 2022-01-19T14:36:47-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/54/eyegate-pharma-reports-first-quarter-2019-financial-results-and-provides-business-update 2022-01-19T14:36:48-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/55/eyegate-files-ide-with-fda-for-prk-pivotal-study 2022-01-19T14:36:48-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/56/eyegate-confirms-path-to-de-novo-filing-with-fda 2022-01-19T14:36:48-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/57/eyegate-pharmaceuticals-reports-full-year-2018-financial-results-and-provides-business-update 2022-01-19T14:36:48-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/58/eyegate-pharmaceuticals-to-present-at-bio-ceo-investor-conference-in-new-york-city 2022-01-19T14:36:49-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/59/eyegate-pharmaceuticals-announces-meeting-date-with-fda 2022-01-19T14:36:49-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/60/eyegate-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-business-update 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/62/eyegate-pharma-announces-positive-results-in-second-prk-study 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/61/eyegate-pharma-announces-positive-results-in-punctate-epitheliopathy-study 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/63/eyegate-pharmaceuticals-signs-technology-transfer-and-license-agreement-with-sentrx-animal-care 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/64/eyegate-pharmaceuticals-granted-additional-180-days-to-comply-with-nasdaq-listing-rules 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/65/eyegate-pharmaceuticals-completes-enrollment-in-both-prk-and-pe-pilot-studies 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/66/eyegate-announces-randomization-of-first-patients-in-study-for-punctate-epitheliopathies 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/67/eyegate-announces-top-line-results-for-phase-3-trial-of-egp-437-in-anterior-uveitis 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/68/eyegate-pharmaceuticals-announces-participation-at-the-h-c-wainwright-20th-annual-global-investment-conference 2022-01-19T14:36:50-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/69/eyegate-announces-enrollment-of-first-patient-in-prk-pilot-study 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/70/eyegate-pharmaceuticals-announces-new-board-member-peter-greenleaf 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/71/eyegate-pharmaceuticals-reports-second-quarter-2018-financial-results-and-provides-business-update 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/72/eyegate-announces-fda-approval-of-two-ide-submissions-for-ocular-bandage-gel 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/73/eyegate-addresses-final-fda-action-item-with-submission-of-ide-amendment-for-ocular-bandage-gel 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/74/eyegate-files-supplement-to-investigational-device-exemption-to-commence-study-in-punctate-epitheliopathy-using-the-eyegate-ocular-bandage-gel 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/75/eyegate-addresses-majority-of-fdas-action-items-with-submission-of-investigational-device-exemption-amendment-for-ocular-bandage-gel 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/76/eyegate-pharmaceuticals-announces-new-board-member-steven-boyd 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/77/eyegate-pharmaceuticals-reports-first-quarter-2018-financial-results-and-provides-business-update 2022-01-19T14:36:51-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/78/eyegate-announces-completion-of-11-25-million-public-offering 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/79/eyegate-announces-11-25-million-public-offering 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/80/eyegate-issued-new-patent-for-iontophoretic-contact-lens-technology 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/81/eyegate-receives-fda-feedback-on-investigational-device-exemption-amendment-for-second-pilot-study-of-ocular-bandage-gel 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/82/eyegate-completes-enrollment-and-receives-milestone-payment-for-confirmatory-phase-3-clinical-study-of-egp-437-in-anterior-uveitis 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/83/eyegate-pharma-to-participate-at-the-30th-annual-roth-conference 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/84/eyegate-pharma-submits-investigational-device-exemption-amendment-for-second-pilot-study-of-ocular-bandage-gel 2022-01-19T14:36:52-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/85/eyegate-pharmaceuticals-reports-full-year-2017-financial-results-and-provides-business-update 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/86/eyegate-to-present-at-the-2018-bio-ceo-investor-conference 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/87/eyegate-announces-top-line-results-for-phase-2b-trial-of-egp-437-in-cataract-surgery 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/88/eyegate-promotes-sarah-romano-to-chief-financial-officer 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/89/eyegate-awarded-new-u-s-patent-for-iontophoretic-delivery-of-corticosteroids-to-the-eye 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/90/eyegate-achieves-75-enrollment-in-pivotal-phase-3-clinical-trial-for-anterior-uveitis-triggering-milestone-payment 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/91/eyegate-pharmaceuticals-reports-third-quarter-2017-financial-results-and-provides-business-update 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/92/eyegate-completes-enrollment-in-phase-2b-clinical-trial-of-egp-437-for-cataract-surgery 2022-01-19T14:36:53-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/93/eyegate-appoints-mike-garanzini-as-chief-commercial-officer-to-develop-and-implement-global-launch-strategy 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/94/eye-care-thought-leaders-join-eyegate-scientific-advisory-board 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/95/eyegate-launches-social-media-pages-to-enhance-investor-and-trade-relationships 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/96/eyegate-pharma-to-present-at-the-19th-annual-rodman-and-renshaw-global-investment-conference 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/97/eyegate-pharmaceuticals-reports-second-quarter-2017-financial-results-and-provides-business-update 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/98/eyegate-pharma-enrolls-first-patient-in-phase-2b-clinical-study-of-egp-437-for-cataract-surgery 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/99/eyegate-announces-completion-of-10-0-million-public-offering 2022-01-19T14:36:54-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/100/eyegate-announces-10-0-million-public-offering 2022-01-19T14:36:55-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/101/eyegate-receives-milestone-payment-from-valeant-pharmaceuticals-for-egp-437-for-post-operative-ocular-inflammation-and-pain-in-ocular-surgery-patients 2022-01-19T14:36:55-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/102/eyegate-pharmaceuticals-reports-first-quarter-2017-financial-results-and-provides-business-update 2022-01-19T14:36:55-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/103/eyegate-submits-investigational-device-exemption-ide-filing-for-second-pilot-study-of-ocular-bandage-gel 2022-01-19T14:36:55-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/104/eyegate-pharma-strengthens-scientific-advisory-board-with-appointments-of-daniel-s-durrie-m-d-and-randall-j-olson-m-d 2022-01-19T14:36:55-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/105/eyegate-pharmaceuticals-reports-full-year-2016-financial-results-and-provides-business-update 2022-01-19T14:36:56-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/106/eyegate-pharmaceuticals-announces-executive-promotions 2022-01-19T14:36:56-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/107/eyegate-pharma-announces-positive-top-line-data-from-first-in-human-pilot-trial-of-ocular-bandage-gel-in-corneal-epithelial-defects 2022-01-19T14:36:56-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/108/eyegate-pharmaceuticals-to-present-at-the-noble-financial-capital-markets-13th-annual-investor-conference 2022-01-19T14:36:56-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/109/eyegate-pharma-awarded-canadian-patent-for-proprietary-iontophoretic-formulation-and-use-of-the-formulation-for-ocular-delivery-of-dexamethasone-phosphate 2022-01-19T14:36:56-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/110/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/111/eyegate-reports-positive-data-from-third-stage-of-phase-1b2a-clinical-trial-of-egp-437-in-cataract-surgery-patients 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/112/fda-confirms-a-510k-de-novo-path-for-eyegates-device-the-ocular-bandage-gel-following-pre-submission-meeting 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/113/eyegate-pharmaceuticals-reports-third-quarter-2016-financial-results-and-provides-business-update 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/114/eyegate-pharmaceuticals-to-present-at-the-2016-aegis-capital-conference 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/115/eyegate-awarded-448185-for-second-year-of-funding-of-phase-ii-sbir-grant-from-u-s-department-of-defense 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/116/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/117/eyegate-pharmaceuticals-to-present-at-the-18th-annual-rodman-and-renshaw-global-investment-conference 2022-01-19T14:36:57-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/118/eyegate-pharmaceuticals-reports-second-quarter-2016-financial-results-and-provides-business-update 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/119/eyegate-announces-positive-top-line-data-from-phase-1b2a-clinical-trial-of-egp-437-for-treatment-of-post-operative-inflammation-and-pain-in-cataract-surgery-patients 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/120/eyegate-announces-completion-of-3-77-million-registered-direct-offering 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/121/eyegate-announces-3-77-million-registered-direct-offering 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/122/eyegate-announces-encouraging-interim-data-from-phase-1b2a-clinical-trial-of-egp-437-for-treatment-of-ocular-inflammation-and-pain-post-cataract-surgery 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/123/eyegate-pharma-announces-at-the-market-issuance-program 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/124/eyegate-pharmaceuticals-reports-first-quarter-2016-financial-results-and-provides-business-update 2022-01-19T14:36:58-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/125/eyegate-pharma-appoints-dr-brenda-k-mann-as-vice-president-research-and-development 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/126/eyegate-pharma-appoints-ryan-r-brenneman-as-chief-financial-officer 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/127/eyegate-pharma-to-present-four-posters-at-arvo-2016-annual-meeting-supporting-development-of-cmha-s 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/128/eyegate-reports-full-year-2015-financial-results-and-provides-business-update 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/129/eyegate-pharma-acquires-jade-therapeutics 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/130/eyegate-receives-additional-milestone-payment-from-valeant-pharmaceuticals-for-egp-437 2022-01-19T14:36:59-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/131/eyegate-pharma-enrolls-first-patient-in-confirmatory-phase-3-clinical-trial-egp-437-006-for-non-infectious-anterior-uveitis 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/132/eyegate-pharmaceuticals-to-present-at-the-noble-financial-capital-markets-12th-annual-investor-conference 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/133/eyegate-reports-third-quarter-2015-financial-results-and-provides-business-update 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/134/eyegate-announces-interim-data-from-phase-1b-2a-clinical-trial-of-iontophoretic-egp-437-ophthalmic-solution-in-macular-edema-patients 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/135/eyegate-pharma-receives-uspto-notice-of-allowance-for-next-generation-of-proprietary-iontophoretic-delivery-system 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/136/eyegate-pharmaceuticals-to-present-at-the-17th-rodman-and-renshaw-2015-annual-global-investment-conference 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/137/eyegate-pharmaceuticals-announces-closing-of-public-offering-of-common-stock-and-warrants 2022-01-19T14:37:00-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/138/eyegate-pharmaceuticals-announces-pricing-of-10000000-public-offering-of-common-stock-and-warrants 2022-01-19T14:37:01-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/139/eyegate-pharma-receives-uspto-notice-of-allowance-for-proprietary-dexamethasone-phosphate-formulation 2022-01-19T14:37:01-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/140/eyegate-pharma-treats-first-patient-in-phase-1b-2a-trial-of-egp-437-in-macular-edema 2022-01-19T14:37:01-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/141/eyegate-signs-licensing-agreement-with-valeant-pharmaceuticals-for-egp-437-combination-product-in-uveitis 2022-01-19T14:37:01-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/142/eyegate-pharma-receives-positive-guidance-from-fda-on-nda-filing-requirements-of-egp-437-for-the-treatment-of-anterior-uveitis 2022-01-19T14:37:01-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/143/eyegate-pharmaceuticals-reports-full-year-2014-financial-results 2022-01-19T14:37:02-05:00 https://ir.kiorapharma.com/news-events/news-releases/detail/144/eyegate-pharmaceuticals-names-michael-b-raizman-md-consulting-chief-medical-officer 2022-01-19T14:37:02-05:00 https://ir.kiorapharma.com/news-events/events/detail/20260226-oppenheimers-36th-annual-healthcare-life-sciences-conference 2026-02-19T16:56:45-05:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000034/wk-form4_1775162820.html 2026-04-02T16:47:57-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000032/wk-form4_1775162772.html 2026-04-02T16:47:52-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000030/wk-form4_1775162730.html 2026-04-02T16:46:13-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000028/kprx-20260401.htm 2026-04-02T16:45:06-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000026/kiorapharmaceuticalsinc-sx.htm 2026-03-25T07:33:23-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000025/kprx-20260325.htm 2026-03-25T07:04:17-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000024/kprx-20251231.htm 2026-03-25T07:03:52-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000012/wk-form4_1773174978.html 2026-03-10T16:42:47-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000013/wk-form4_1773175009.html 2026-03-10T16:42:19-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000014/wk-form4_1773175029.html 2026-03-10T16:42:10-04:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000007/wk-form4_1772823830.html 2026-03-06T14:04:23-05:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000006/wk-form4_1772823806.html 2026-03-06T14:04:01-05:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001622627-26-000010/primary_doc.html 2026-02-11T14:00:55-05:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001493152-26-004296/primary_doc.html 2026-01-29T20:29:06-05:00 https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001104659-25-112617/primary_doc.html 2025-11-14T16:40:18-05:00 https://ir.kiorapharma.com/privacy-policy https://ir.kiorapharma.com/disclaimer https://ir.kiorapharma.com/sitemap https://ir.kiorapharma.com/accessibility-statement